Clinical trial

PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC

NCT04284202

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2020-03-01

PhasePHASE2

Study timeline

Study start (estimated)2020-03-01Date precision: day

Registry last updated2020-02-25

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

NSCLC Stage IVunresolved

ARID1Aunresolved

PD-1unresolved

Interventions

PD-1 plus DasatinibDRUG

Sponsors & collaborators

The Affiliated Hospital of Qingdao Universitylead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04284202 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.